China, Oct. 21 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Clinical study on BCMA-targeted T-cell engaging antibody therapy for immune thrombotic thrombocytopenic purpura resistant to rituximab and/or daratumumab'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600134682
Registration Time: 2026/10/19
Type: Interventional study
Primary Sponsor: THE FIRST AFFILIATED HOSPITAL OF USTC ANHUI PROVINCAL HOSPITAL
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=348288
Published by HT Digital Content Services with permission from Health Daily Digest....